Claude agents find CRISPR-like enzyme system at Anthropic

Anthropic said Sep 23 that Claude agents, searching DNA for unusual reverse transcriptases with only high-level human direction, identified a previously uncharacterized array-associated reverse transcriptase (ART) system — a reverse transcriptase beside a CRISPR-like DNA repeat array and an accessory protein — after a run the company pegs at roughly 950 agents, 21 hours, and 210 million tokens, according to its research post.

What the company says was found: ART appears mainly in bacteriophages. The underlying RT in a jumbo phage had been noted before; Anthropic says Claude was first to flag the associated non-coding repeat array and partner gene as a system. Early lab work (human scientists, BSL-1/2 Bay Area wet lab) shows the array is expressed as distinct short RNAs. Function remains open; a pre-print is posted with the announcement.

Why it matters for markets and science: Frontier labs are spending agent compute and wet-lab capacity on genome mining — not just model demos. A company-claimed autonomous hit on a CRISPR-adjacent enzyme package is a stake in how AI labs price discovery labor and biology R&D. That is lab and agent spend, not a tip.

Stake: Anthropic’s new life-sciences lab and training stack; biotech and gene-editing shops watching programmable DNA tools; CRISPR pioneers and genome-mining competitors; hyperscalers selling the token burn behind multi-agent sweeps.

What’s next: Pre-print peer reception; any functional readout on ART (cut/copy/paste-class activity); how Anthropic productizes Claude Science / multi-agent biology harnesses for outside labs.

— Nico Valdez